Institut Claudius Regaud

Toulouse, France

30 recruiting

Showing 120 of 44 trials

Recruiting
Phase 3

Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers

Squamous Cell Carcinoma of Head and Neck
UNICANCER102 enrolled26 locationsNCT04747054
Recruiting

French Childhood Cancer Survivor Study

Childhood Solid Tumor
Institut National de la Santé Et de la Recherche Médicale, France18,000 enrolled36 locationsNCT01620372
Recruiting
Phase 2

Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment

Malignant Solid Neoplasms
Centre Leon Berard900 enrolled7 locationsNCT02029001
Recruiting
Phase 3

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

Endometrial Cancer
Daiichi Sankyo710 enrolled75 locationsNCT07022483
Recruiting
Phase 2

Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC

Triple-Negative Breast Cancer
UNICANCER354 enrolled44 locationsNCT06078384
Recruiting
Phase 3

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

Glioblastoma
NovoCure GmbH741 enrolled102 locationsNCT06556563
Recruiting
Phase 1Phase 2

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

Metastatic Breast CancerLocally Advanced Breast CancerUnresectable Breast Carcinoma
BioNTech SE380 enrolled68 locationsNCT06827236
Recruiting
Phase 1Phase 2

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

Advanced Solid TumorMetastatic Solid Tumor
Daiichi Sankyo590 enrolled33 locationsNCT05875168
Recruiting
Phase 3

A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

Cancer
Hoffmann-La Roche100 enrolled67 locationsNCT05862285
Recruiting
Phase 3

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+3 more
Relay Therapeutics, Inc.540 enrolled211 locationsNCT06982521
Recruiting
Phase 2

A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.

Malignant Solid Tumor
Centre Leon Berard455 enrolled13 locationsNCT04116541
Recruiting
Phase 1Phase 2

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Breast CancerSolid Tumors, Adult
Eli Lilly and Company880 enrolled65 locationsNCT05768139
Recruiting
Phase 1

A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

Leukemia, Myeloid, AcuteMyelodysplastic Neoplasms
Janssen Research & Development, LLC155 enrolled9 locationsNCT06651229
Recruiting
Phase 1

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Relapsed or Refractory Multiple MyelomaPreviously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC180 enrolled29 locationsNCT05652335
Recruiting
Phase 1Phase 2

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Breast CancerTriple-Negative Breast CancerColorectal, Cancer+26 more
PMV Pharmaceuticals, Inc300 enrolled77 locationsNCT04585750
Recruiting
Phase 1Phase 2

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

Relapsed/Refractory Non-Hodgkin Lymphoma
Bristol-Myers Squibb460 enrolled67 locationsNCT06090539
Recruiting
Phase 3

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Metastatic Breast Cancer
LeonaBio600 enrolled224 locationsNCT05696626
Recruiting
Phase 1Phase 2

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Breast NeoplasmsBreast DiseasesNeoplasms+5 more
Stemline Therapeutics, Inc.73 enrolled86 locationsNCT05386108
Recruiting

Multiomic Approach to Radioresistance of Ependymomas in Children and Adolescents

Pediatric Solid TumorEpendymoma of Brain
Institut Claudius Regaud370 enrolled1 locationNCT05151718
Recruiting
Phase 3

Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib

Breast Cancer
UNICANCER3,902 enrolled138 locationsNCT07237256